Voltar à classificação

Exponent, Inc. (EXPO)

NEUTRAL
IndustrialsEngineering & ConstructionUnited States

Fundamental

65

Preço

$69.78

Capitalização de Mercado

$3.39B

Parte 1 · Quanto vale a empresa

Visão Geral

Exponent, Inc., together with its subsidiaries, operates as a science and engineering consulting company in the United States and internationally. The company operates in two segments, Engineering and Other Scientific, and Environmental and Health. It provides services in the areas of biomechanics, biomedical engineering and sciences, civil and structural engineering, construction consulting, data sciences, electrical engineering and computer science, human factors, materials and corrosion engineering, mechanical engineering, metallurgical and corrosion engineering polymer and chemistry, thermal sciences, and vehicle engineering. The company also offers services in the areas of chemical regulation and food safety, ecological and biological sciences, environmental and earth sciences, and health sciences. In addition, it provides proactive and reactive product safety, litigation support, and technical, regulatory services. It serves clients in chemical, construction, consumer products, energy, food, beverage and nutrition, government, life sciences, insurance, manufacturing, technology, industrial equipment, transportation, and other sectors. The company was formerly known as The Failure Group, Inc. and changed its name to Exponent, Inc. in 1998. The company was founded in 1967 and is headquartered in Menlo Park, California.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

No editorial profile for this company yet

No competitor list for this company yet.

Balanço & Liquidez

Receita

$632M

Últimos 12 meses (até 03/07/2026)

Resultado Líquido

$112M

Últimos 12 meses (até 03/07/2026)

Fluxo de Caixa Livre

$122M

Capital Próprio Total

$390M

Passivo Total

$387M

Rácio de Liquidez

1.98

Cobertura de Juros

-

Dívida/EBITDA

0.62

Resultados Por Ação

Receita & Resultado Líquido

Fluxo de Caixa Livre

Decomposição dos Resultados

Demonstração histórica

Margens ao longo do tempo

A dívida ao longo do tempo

Quanto pesa a dívida

Grelha do crescimento

Crescimento — Receitas

Estimativa de Valor Justo

General caseJustamente Valorizada

Valor Justo

$63.65

Preço Atual

$69.78

Margem de Segurança

-9.6%

Intervalo de Valor Justo

$45.42 - $81.89

Métodos de Estimativa

Analyst price target:$84.00
Discounted cash flow (DCF):$62.39
Earnings multiple (P/E):$59.46
Graham growth formula:$40.11
Earnings power value (EPV):$22.15
Justified P/B:$43.75
Dividend discount (Gordon):$29.62
P/FFO, funds from operations:Not enough data to compute it
Mid-cycle earnings:$60.80
Revenue multiple:Not enough data to compute it
Consenso dos Analistas:Compra Forte (8B / 2H / 0S)
Última Surpresa de Resultados:+6.95%

Métricas de Avaliação

Rácio P/E

31.88

ROE

27.2%

Rácio P/B

11.66

P/FCF

31.00

Margem Bruta

-

ROIC

20.4%

Radar de Rentabilidade

Value Creation (Economic Moat)

ROIC

20.4%

WACC

8.1%

ROIC − WACC

+12.3 pp

ROIC exceeds the cost of capital — the company is creating value for shareholders.

Critérios de Análise Fundamental

Aprovado (18)

  • EPS shows upward trend
  • Price CAGR 8.82%
  • ROIC 20.4%
  • Debt/Equity ratio
  • Operating Margin 20.2%
  • Positive Free Cash Flow
  • CapEx intensity
  • Current Ratio
  • Debt/EBITDA
  • Return on Tangible Assets
  • Low reliance on intangibles
  • ROE 27.9%
  • Revenue Growth 5Y 7.8%
  • Analyst Consensus 80% Buy
  • Earnings Surprise avg 4.3%
  • Earnings Quality (OCF/NI) 1.06
  • Share Dilution -0.9%
  • Piotroski F-Score 5/9

Reprovado (7)

  • EPS CAGR 2.16%
  • P/FCF 31.00
  • P/B Ratio 11.66
  • Price below Graham Number
  • DCF valuation (Overvalued)
  • PEG Ratio 4.90
  • Net Margin Trend 17.7% vs 18.3%

Indisponível (3)

  • Gross Margin NaN%
  • Dividend Payout NaN%
  • Interest Coverage

Piotroski F-Score

5/9

Sinais mistos: algumas áreas requerem atenção

score
criteria

Qualidade dos Resultados

1.06

Alta qualidade: resultados respaldados por caixa

Diluição de Ações

-0.9%

A recomprar ações. Favorável ao acionista

Governação

Equipa Executiva

NomeCargoIdade
Dr. Catherine Ford Corrigan P.E., Ph.D.CEO & Director56
Mr. Richard L. Schlenker Jr.Executive VP, Corporate Secretary & Director59
Dr. Maureen T. F. Reitman F.S.P.E., P.E., Sc.D.Group Vice President56
Dr. Joseph Rakow Ph.D.Group Vice President48
Dr. Joseph Sala Ph.D.Group Vice President48
Dr. John D. Pye P.E., Ph.D.President54
Dr. Bernard Ross P.E., Ph.D.Co-Founder & Principal Engineer-
Mr. Eric R. AndersonChief Financial Officer50
Ms. Gina FlynnVP of Legal & General Counsel-
Mr. Brian KundertChief Human Resources Officer50

Risco de Auditoria

9

Risco do Conselho

2

Risco de Remuneração

4

Risco dos Direitos dos Acionistas

2

Parte 2 · O preço e o momento de entrar

Esta parte não serve para saber se a empresa vale: serve para escolher quando comprá-la, depois que os fundamentos te convenceram. Dentro: análise técnica, potencial, quedas históricas, exposição gama.

Latest News

Recent headlines for EXPO, sourced from Markets Gazette.

No recent news for EXPO.